<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32</article-id><article-id pub-id-type="doi">10.15789/2220-7619-2011-1-85-91</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">VACCINATION OF PATIENTS WITH ONCOLOGY DISEASES AGAINST MEASLES AND MUMPS</article-title><trans-title-group xml:lang="ru"><trans-title>ВАКЦИНАЦИЯ ПАЦИЕНТОВ С ОНКОЛОГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ПРОТИВ КОРИ И ЭПИДЕМИЧЕСКОГО ПАРОТИТА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kharit</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Харит</surname><given-names>С. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., профессор, зав. отделом профилактики инфекционных болезней</p><p>197022, Санкт-Петербург, ул. Проф. Попова, 9</p></bio><email>kharits-s@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cherniaeva</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Черняева</surname><given-names>Т. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kharits-s@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cherniaeva</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Черняева</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kharits-s@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Brusov</surname><given-names>N. K.</given-names></name><name xml:lang="ru"><surname>Брусов</surname><given-names>Н. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kharits-s@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГУ Научно-исследовательский институт детских инфекций ФМБА России, Санкт-Петербург</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2011</year></pub-date><volume>1</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>85</fpage><lpage>91</lpage><history><date date-type="received" iso-8601-date="2014-06-26"><day>26</day><month>06</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-06-26"><day>26</day><month>06</month><year>2014</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Kharit S.M., Cherniaeva T.V., Cherniaeva E.V., Brusov N.K.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Харит С.М., Черняева Т.В., Черняева Е.В., Брусов Н.К.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Kharit S.M., Cherniaeva T.V., Cherniaeva E.V., Brusov N.K.</copyright-holder><copyright-holder xml:lang="ru">Харит С.М., Черняева Т.В., Черняева Е.В., Брусов Н.К.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/32">https://iimmun.ru/iimm/article/view/32</self-uri><abstract xml:lang="en"><p><bold>Abstract.</bold> One hundred and seven children (45 girls and 62 boys) in the age of 20 months — 14 years old (mean 9,62±0,37) suffered from acute lymphoblast leukosis and solid tumors in history have been examined in the clinic of Research Institute of children infections of FMBA. The vaccination history was studied in all children and the titers of specific antibodies to measles and mumps viruses as well as immune status were determined. 83,8% and 85,4% of studied children had no protection against measles and mumps respectively or had low titers of antibodies. Immunological examination of these children conducted within 4 months after finishing of therapy revealed absence of immunodeficiency. It gave opportunities to vaccinate or revaccinate these children against mentioned infections. Fifty three children were immunized against measles and 47 — against mumps. Application of live vaccines was safe because majority of vaccinated against measles (81,1%) and mumps (82,9%) children had mild vaccination process. It was established that to increase immunological efficacy of vaccination using of polyoxidony during 5 days before vaccination and 5 days after vaccination is reasonable.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Резюме. </bold>На базе клиники ФГУ НИИДИ ФМБА России обследовано 107 детей (45 девочек и 62 мальчика) в возрасте 20 месяцев — 14 лет (9,62±0,37 лет) с острым лимфобластным лейкозом и солидными опухолями в анамнезе. У всех детей изучен прививочный анамнез, определены титры специфических антител к кори, паротиту, иммунный статус. Не защищены и имеют низкие титры против кори в 83,8%, против паротита — в 85,4%. Иммунологическое обследование этих детей уже через 4 месяца после окончания терапии свидетельствует об отсутствии признаков иммунодефицитного состояния и возможности проведения вакцинации (ревакцинации). Против кори привито 53 ребенка, против паротита — 47. Показана безопасность введения живых вакцин, так как большинство привитых против кори (81,1%) и паротита (82,9%) имели гладкий вакцинальный процесс. Установлено, что для увеличения иммунологической эффективности вакцинации целесообразно применение полиоксидония за 5 дней до и 5 дней после прививки.</p></trans-abstract><kwd-group xml:lang="en"><kwd>vaccination against measles and mumps</kwd><kwd>oncology diseases</kwd><kwd>children</kwd><kwd>specific antibodies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вакцинация против кори и паротита</kwd><kwd>онкологические заболевания</kwd><kwd>дети</kwd><kwd>специфические антитела</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Костинов М.П. Вакцинация детей с нарушенным состоянием здоровья: Практическое руководство. — М., 2000. — 152 c.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Парахонский А.П. Иммунный дисбаланс при опухолевых заболеваниях и его коррекция // Иммунитет и болезни: от теории к терапии: Материалы междунар. конгр. — М., 2005. — С. 187.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Пинегин Б.В. Новые разработки на основе полиоксидония / Под ред. Б.В. Пинегина, И.Н. Царева. — М.: НПО Петровакс Фарм, 2004. — 24 с.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Совершенствование организации специализирован ной помощи детям с онкогематологическими заболеваниями в Российской Федерации: Решение коллегии МЗ РФ; протокол № 3 от 19.02.2002.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Avigan D., Pirofski L., Hillard M. Vaccination against infectious following hematopoietic stem cell transplantation // Biol. Blood. Marrow Transplant. — 2001. — N 7. — P. 171–183.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Berkelhamer S., Borock E., Elsen C., Englund J., Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children / Clin. Infect. Dis. — 2001. — Vol. 32, N 7. — P. 1090–1094.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Blythe T., Hahn T., Wall D., Camitta B. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (All) after first bone marrow or extramedullary relapse // Pediatr. Blood Cancer. — 2004. — Vol. 43, N 5. — P. 571–579.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Emir S., Buyukpamukcu M., Koseoglu V., Hascelik G., Akyuz C., Kutluk T., Varan A. Varicella vaccination in children with lymphoma and solid tumours // Postgrad. Med. J. — 2006. — N 82. — P. 760–762.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Gray M.M., Hann I.M., Glass S., Eden O.B., Jones P.M., Stevens R.F. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centers: a retrospective review // Br. Med. J. (Clin. Res. Ed.). — 1987. — Vol. 295, N 6589. — P. 19–22.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Molldrem J.J. Vaccination for Leukemia // Biol. Blood Marrow Transplant. — 2006. — Vol. 12, Iss. 1. (Supp. 1). — P. 13–18.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Moritz B., Eder J., Meister B. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy // Med. Pediatr. Oncol. — 2001. — Vol. 36, N 2. — P. 283–289.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Nilsson A., De Milito A., Engstrom P., Nordin M., Narita M., Grillner L. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antige // Pediatrics. — 2002. – Vol. 109, N 6. — e91.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Okada H., Kobune F., Sato T.A. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients // Arch Virol. — 2000. — Vol. 145, N 5. — P. 905–920.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Plotkin S.A., Orenstein W.A. Vaccines. — 4 ed. — USA: Elsevier one, 2004. — 1662 p.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Torigoe S., Hirai S., Oitani K., Ito M., Ihara T., Iwasa T., Kamiya H., Sakurai M., Ueda S., Yamanishi K. Application of live attenuated measles and mumps vaccines in children with acute leukemia // Biken J. — 1981. — Vol. 24, N 4. — P. 147–151.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Zignol M., Peracchi M., Tridello G., Pillon M., Fregonese F., D'Elia R., Zanesco L., Cesaro S. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer // Cancer. — 2004. — Vol. 101, N 3. — P. 635–641.</mixed-citation></ref></ref-list></back></article>
